Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton, NJ, 4Safety, Bristol-Myers Squibb, San Diego, CA...
Main Authors: | MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-05-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/safety-and-tolerability-of-exenatide-once-weekly-in-patients-with-type-peer-reviewed-article-DMSO |
Similar Items
-
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
by: Gurney K, et al.
Published: (2012-02-01) -
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
by: MacConell L, et al.
Published: (2013-01-01) -
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
by: Goud A, et al.
Published: (2015-10-01) -
Exenatide once weekly: clinical outcomes and patient satisfaction
by: Biju Jose1, et al.
Published: (2010-08-01)